Per the grant, here is the brick. On June 2, 2026, CRISPR Therapeutics AG was issued US12644123B2, "Modulating expression of ALAS1 (5'-aminolevulinate synthase 1) gene." The CPC classifications — C12N 15/1137 (regulation of gene expression), C12N 9/22 (nucleases), C12N 15/88 (delivery) — place it precisely in the gene-editing therapeutic stack: a target, an editing machinery, and a delivery method.
Why a deals desk cares about one grant: gene-editing companies are valued on the strength and breadth of issued IP, because the platform alone is not bankable — the enforceable claims are. An issued grant like this is the kind of asset that underwrites a licensing deal, anchors a milestone schedule, or supports the equity story behind a raise. It is a floor under the valuation in a way a pending application or a conference slide is not.
The structure point an investor should hold onto: one grant is a brick, not the building. A gene-editing valuation rests on the cumulative estate — many grants across targets, machinery, and delivery — plus the freedom to operate around the foundational CRISPR patents held by others. A single target-specific grant supports the value of the program it covers; it does not, by itself, clear the company's path across the whole platform.
What this document does not promise: clinical success, an approval, or freedom from the broader CRISPR IP thicket. A grant on modulating one gene's expression is an exclusivity claim on a method, not a guarantee that the therapy works or that the company can practice it without licensing someone else's foundational claims. Those are separate facts, in separate records.
The disciplined business read: when a gene-editing company's value is in question, count the issued grants and read what each one actually covers, target by target. CRISPR Therapeutics' ALAS1 grant is a real, recent, target-specific asset. It is one of the bricks a deal is built on — and naming it specifically is how a deals desk prices the pipeline instead of the press release.